Quick Answer
Arcutis Biotherapeutics, Inc. reported Operating Income Loss of -$12.23 million for the year ending 2025.
- Arcutis Biotherapeutics, Inc. showed an increase of +90.5% in Operating Income Loss from 2024 to 2025.
- This data is from Arcutis Biotherapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 25, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2019: -$6.95 million | Q2 2019: -$8.54 million | Q3 2019: -$14.65 million | Q1 2020: -$28.65 million | Q2 2020: -$35.63 million | Q3 2020: -$38.30 million | Q1 2021: -$36.09 million | Q2 2021: -$42.08 million | Q3 2021: -$57.08 million | Q1 2022: -$62.63 million | Q2 2022: -$65.83 million | Q3 2022: -$104.75 million | Q1 2023: -$76.27 million | Q2 2023: -$66.76 million | Q3 2023: -$36.90 million | Q1 2024: -$31.62 million | Q2 2024: -$50.08 million | Q3 2024: -$39.07 million | Q1 2025: -$24.53 million | Q2 2025: -$14.61 million | Q3 2025: $8.53 million.
- Over the full 8 years of available data (2018 to 2025), Arcutis Biotherapeutics, Inc.'s Operating Income Loss has grown by 38.0%.
- Historical annual values: Fiscal year 2025: -$12.23 million | Fiscal year 2024: -$128.40 million | Fiscal year 2023: -$241.10 million | Fiscal year 2022: -$301.63 million | Fiscal year 2021: -$206.53 million | Fiscal year 2020: -$136.65 million | Fiscal year 2019: -$43.13 million | Fiscal year 2018: -$19.74 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: